In my opinion this is a case study in regulatory capture. The FDA ignored their own advisory committee and approved it based on flimsy data. Now Biogen will rake in the cash, and other companies will take notice.

I disagree. It is an opportunity for alzheimer's patients that cannot be missed; FDA approval is conditional and can be revoked if further studies reveal lacking evidence.